1. Measure Details
2. Measure Parameters
3. Meeting the Measure in Elation
4. Measure Information
1. Measure Details:
Percentage of adults 50-75 years of age who had appropriate screening for colorectal cancer
2. Measure Parameters:
Numerator: Patients with one or more screenings for colorectal cancer. Appropriate screenings are defined by any one of the following criteria:
- Fecal occult blood test (FOBT) during the measurement period
- Flexible sigmoidoscopy during the measurement period or the three years prior to the measurement period
- Colonoscopy during the measurement period or the eight years prior to the measurement period
Denominator: Patients 50-75 years of age with a visit during the measurement period.
Exclusions/Exceptions: Patients with a diagnosis or past history of total colectomy or colorectal cancer.
3. Elation Workflows
Documenting a screening from a visit note:
1/ Elation's Clinical Decision Support Feature allows you to easily document screenings. When a patient is due for a Colorectal Cancer Screening, an alert will report at the top of the patient's visit note. Options for selecting the measure will appear after clicking address:
Documenting a screening from the patient chart:
1/ For a patient in the denominator, scroll to the bottom of their clinical profile, where their Health Maintenance items appear.
2/ Click on Colorectal Screening, indicate the date of the patient’s most recent Colorectal Screening (CQM FOBT, CQM Colonoscopy, or CQM Flexible sigmoidoscopy), and click Save New.
Tag a report in the patient’s record with the “CQM: Colonoscopy” or “CQM: Flexible sigmoidoscopy” or “CQM: FOBT” document tag. This alone will meet the health maintenance requirement.
4. Measure Information
An estimated 132,700 men and women were diagnosed with colon or rectal cancer in 2015. In the same year, 49,700 were estimated to have died from the disease, making colorectal cancer the third leading cause of cancer death in the United States. Screening for colorectal cancer is extremely important as there are no signs or symptoms of the cancer in the early stages. If the disease is caught in its earliest stages, it has a five-year survival rate of 90%. The U.S. Preventive Services Task Force has identified fecal occult blood tests, colonoscopy, and flexible sigmoidoscopy as effective screening methods (United States Preventive Services Task Force 2008).